SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Anderson IM. Selective serotonin re-uptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. 2000; 58: 1936.
  • 2
    Kasper S, Pletan Y, Solles A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: A summary of clinical trial results. Int. Clin. Psychopharmacol. 1996; 11 (Suppl. 4): 3539.
  • 3
    Mochizuki D, Tsujita R, Yamada S et al. Neurochemical and behavioral characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl) 2002; 162: 323332.
  • 4
    Ito K, Yoshida K, Sato K et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res. 2002; 111: 235239.
  • 5
    Yoshida K, Ito K, Sato K et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002; 26: 383386.
  • 6
    Higuchi H, Yoshida K, Takahashi H et al. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Hum. Psychopharmacol. 2003; 18: 255259.
  • 7
    Cohen LS. Gender-specific considerations in the treatment of mood disorders in women across the life cycle. J. Clin. Psychiatry 2003; 64 (Suppl. 15): 1829.
  • 8
    Kornstein SG, Schatzberg AF, Thase ME et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am. J. Psychiatry 2000; 157: 14451452.
  • 9
    Martenyi F, Dossenbach M, Mraz K, Metcalfe S. Gender differences in the efficacy of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur. Neuropsychopharmacol. 2001; 11: 227232.
  • 10
    Hildebrandt MG, Steyerberg EW, Stage KB. Are gender differences important for the clinical effects of antidepressants? Am. J. Psychiatry 2003; 160: 16431650.
  • 11
    Thase ME, Entsuah R, Cantillon M, Kornstein SG. Relative antidepressant efficacy of venlafaxine and SSRIs: sex–age interactions. J. Womens Health (Larchmt) 2005; 14: 609616.
  • 12
    Morishita S, Arita S. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender. Eur. Psychiatry 2003; 18: 418420.
  • 13
    Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979; 134: 383389.
  • 14
    Crowley WR, Filicori M. The physiology of GnRH secretion in man and woman. Recent Prog. Horm. Res. 1985; 41: 473531.
  • 15
    Wise PM, Krajnak KM, Kashon ML. Menopause: The aging multiple pacemakers. Science 1996; 273: 6770.
  • 16
    Ohkubo T, Shimoyama R, Otani K, Yoshida K, Higuchi H, Shimizu T. High-performance liquid chromatographic determination of fluvoxamine and fluvoxamino acid in human plasma. Anal. Sci. 2003; 19: 859864.
  • 17
    Quitkin FM, Stewart JW, McGrath PJ et al. Are there differences between women's and men's antidepressant response? Am. J. Psychiatry 2002; 159: 18481854.
  • 18
    Halbreich U, Rojansky N, Palter S, Tworek H, Hissin P, Wang K. Estrogen augments serotonergic activity in postmenopausal women. Biol. Psychiatry 1995; 37: 434441.
  • 19
    Matsumoto A, Arai Y, Osanai M. Estrogen stimulates neuronal plasticity in the deafferented hypothalamic arcuate nucleus in aged female rats. Neurosci. Res. 1985; 2: 412418.
  • 20
    McEwen BS, Alves SE, Bulloch K. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997; 48 (Suppl. 7): 815.
  • 21
    Schneider LS, Small GW, Hamilton SH et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am. J. Geriatr. Psychiatry 1997; 5: 97106.
  • 22
    Arranz B, Eriksson A, Mellerup E, Plenge P, Marcusson J. Effect of aging in human pre- and postsynaptic serotonin binding sites. Brain Res. 1993; 620: 163166.
  • 23
    Gorman JM, Kent JM. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J. Clin. Psychiatry 1999; 60 (Suppl. 4): 3338.